Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tamara Chernichovski is active.

Publication


Featured researches published by Tamara Chernichovski.


Journal of Vascular Research | 2011

Hyperuricemia Attenuates Aortic Nitric Oxide Generation, through Inhibition of Arginine Transport, in Rats

Idit F. Schwartz; Ayelet Grupper; Tamara Chernichovski; Avishai Grupper; Oren Hillel; Anat Engel; Doron Schwartz

Objectives: Hyperuricemia provokes endothelial dysfunction (ECD). Decreased endothelial nitric oxide synthase (eNOS) activity is an important source of ECD. Cationic amino acid transporter-1 (CAT-1) is the specific arginine transporter for eNOS. We hypothesize that hyperuricemia inhibits arginine uptake. Methods: Experiments were performed in freshly harvested aortas from untreated animals and rats fed with oxonic acid (hyperuricemia), and compared to hyperuricemic rats treated with either allopurinol, benzbromarone or arginine. Results: Arginine transport was significantly decreased in hyperuricemia. Benzbromarone and arginine prevented the decrease in arginine transport in hyperuricemic rats while allopurinol did not. Arginine transport was significantly decreased in control rats treated with allopurinol. Blood pressure response to acetylcholine was significantly attenuated in hyperuricemic rats, an effect which was prevented in all other experimental groups. L-NAME inhibitable cGMP response to carbamyl-choline was significantly decreased in hyperuricemic rats and this was completely prevented by both benzbromarone and arginine, while allopurinol partially prevented the aforementioned phenomenon. Hyperuricemia induced a significant increase in protein nitration that was prevented by benzbromarone, allopurinol, and arginine. Protein abundance of CAT-1, PKCα, and phosphorylated PKCα remained unchanged in all experimental groups. Conclusions: In hyperuricemia, the decrease in aortic eNOS activity is predominantly the result of attenuated arginine uptake.


American Journal of Physiology-regulatory Integrative and Comparative Physiology | 2015

Estradiol augments while progesterone inhibits arginine transport in human endothelial cells through modulation of cationic amino acid transporter-1

Ohad S. Bentur; Doron Schwartz; Tamara Chernichovski; Merav Ingbir; Talia Weinstein; Gil Chernin; Idit F. Schwartz

Decreased generation of nitric oxide (NO) by endothelial NO synthase (eNOS) characterizes endothelial dysfunction (ECD). Delivery of arginine to eNOS by cationic amino acid transporter-1 (CAT-1) was shown to modulate eNOS activity. We found in female rats, but not in males, that CAT-1 activity is preserved with age and in chronic renal failure, two experimental models of ECD. In contrast, during pregnancy CAT-1 is inhibited. We hypothesize that female sex hormones regulate arginine transport. Arginine uptake in human umbilical vein endothelial cells (HUVEC) was determined following incubation with either 17β-estradiol (E2) or progesterone. Exposure to E2 (50 and 100 nM) for 30 min resulted in a significant increase in arginine transport and reduction in phosphorylated CAT-1 (the inactive form) protein content. This was coupled with a decrease in phosphorylated MAPK/extracellular signal-regulated kinase (ERK) 1/2. Progesterone (1 and 100 pM for 30 min) attenuated arginine uptake and increased phosphorylated CAT-1, phosphorylated protein kinase Cα (PKCα), and phosphorylated ERK1/2 protein content. GO-6976 (PKCα inhibitor) prevented the progesterone-induced decrease in arginine transport. Coincubation with both progesterone and estrogen for 30 min resulted in attenuated arginine transport. While estradiol increases arginine transport and CAT-1 activity through modulation of constitutive signaling transduction pathways involving ERK, progesterone inhibits arginine transport and CAT-1 via both PKCα and ERK1/2 phosphorylation, an effect that predominates over estradiol.


Vascular Medicine | 2010

Aortic arginine transport is attenuated, through post-translational modulation of CAT-1 by PKCα, in old male rats

Idit F. Schwartz; Tamara Chernichovski; Doron Schwartz

Experimental models using rats suggest that decreased endothelial nitric oxide synthase (eNOS) activity in old males promotes renal atherosclerosis, whereas females are protected. We aimed to explore whether aging alters aortic arginine uptake by CAT-1, the selective arginine supplier to eNOS in rats. Arginine uptake by freshly harvested aortic rings from young males (9 weeks) was significantly higher than in young females. Old males (18 months) exhibited a significant decrease in arginine transport compared to young males, whereas no differences were observed between old and young females. Cationic amino acid transporter-1 (CAT-1) abundance remained unchanged in all experimental groups. The abundance of protein kinase C α (PKCα), a CAT-1 inhibitor, was significantly augmented in old versus young males while no differences were detected between old and young females. Phosphorylated PKCα was significantly increased in old rats of both sexes. αTocopherol, a PKC inhibitor, produced a significant increase in arginine transport in old males only. In conclusion, aortic arginine transport by CAT-1 is attenuated in old male rats through upregulation of PKCα. In old females, aortic arginine transport is protected from the effects of PKCα by an unknown mechanism.


American Journal of Physiology-renal Physiology | 2014

l-Arginine improves endothelial function, independently of arginine uptake, in aortas from chronic renal failure female rats

Nachum Nesher; Inna Frolkis; Doron Schwartz; Tamara Chernichovski; Sharon Levi; Yael Pri-Paz; Gil Chernin; Alexander Shtabsky; Yanai Ben-Gal; Yossi Paz; Idit F. Schwartz

Endothelial cell dysfunction (ECD) is a common feature of chronic renal failure (CRF). Defective nitric oxide (NO) generation due to decreased endothelial nitric oxide synthase (eNOS) activity is a crucial parameter characterizing ECD. Decreased activity of cationic amino acid transporter-1 (CAT-1), the selective arginine transporter of eNOS, has been shown to inhibit eNOS in uremia. Recently, we failed to demonstrate a decrease in glomerular arginine transport in uremic female rats (Schwartz IF, Grupper A, Soetendorp H, Hillel O, Laron I, Chernichovski T, Ingbir M, Shtabski A, Weinstein T, Chernin G, Shashar M, Hershkoviz R, Schwartz D. Am J Physiol Renal Physiol 303: F396-F404, 2012). The current experiments were designed to determine whether sexual dimorphism which characterizes glomerular arginine transport system in uremia involves the systemic vasculature as well and to assess the effect of L-arginine in such conditions. Contractile and vasodilatory responses, ultrastructural changes, and measures of the L-arginine-NO system were performed in thoracic aortas of female rats subjected to 5/6 nephrectomy. The contractile response to KCl was significantly reduced, and acetylcholine-induced vasodilation was significantly impaired in aortas from CRF dames compared with healthy rats. Both of these findings were prevented by the administration of arginine in the drinking water. The decrease in both cGMP generation, a measure of eNOS activity, and aortic eNOS and phosphorylated eNOS abundance observed in CRF rats was completely abolished by l-arginine, while arginine transport and CAT-1 protein were unchanged in all experimental groups. Arginine decreased both serum levels of advanced glycation end products and the asymmetrical dimethylarginine/arginine ratio and restored the endothelial ultrastructure in CRF rats. In conclusion. arginine administration has a profound beneficial effect on ECD, independently of cellular arginine uptake, in CRF female rats.


Cryobiology | 2016

Dimethyl sulfoxide attenuates nitric oxide generation via modulation of cationic amino acid transporter-1 in human umbilical vein endothelial cells.

Ohad S. Bentur; Tamara Chernichovski; Merav Ingbir; Talia Weinstein; Idit F. Schwartz

Dimethyl sulfoxide (DMSO) is a solvent that is commonly used in medicine. Conflicting data exist as to its effects on endothelial function. Endothelial cell dysfunction (ECD) is characterized by decreased endothelial nitric oxide synthase (eNOS) activity. Cationic amino acid transporter-1 (CAT-1), the specific arginine transporter for eNOS, has been shown to modulate eNOS activity. We hypothesize that DMSO inhibits eNOS activity through modulation of its selective arginine supplier CAT-1. We studied the effect of DMSO on arginine transport, NO2/NO3 generation as an index of NO production, as well as CAT-1 and Protein Kinase C alpha (PKC-α) (CAT-1 inhibitor) protein expression in human umbilical vein endothelial cell cultures (HUVECs). DMSO 2.5% and 3.5% (v/v) significantly attenuated arginine transport, a phenomenon which was prevented by co-incubation with l-arginine (1xa0mM). The aforementioned findings were accompanied by a decrease in NO2/NO3 generation. DMSO significantly increased the abundance of phosphorylated CAT-1 (the inactive form) and phosphorylated PKC-α protein, an effect that was attenuated by l-arginine. GO 6976 (PKC-α antagonist) prevented the decrease in arginine transport caused by DMSO. DMSO also induced profound transient morphological changes in HUVECs structure but these were not related to its effect on arginine transport. In conclusion, DMSO inhibits NO generation by endothelial cells through modulation of CAT-1 activity.


Kidney & Blood Pressure Research | 2008

Arginine Transport Is Augmented, through Modulation of Cationic Amino Acid Transporter-1, in Obstructive Uropathy in Rats

Idit F. Schwartz; Aharon Davidovitz; Tamara Chernichovski; Nomi Levin-Iaina; Hanan Guzner-Gur; Yoram Levo; Doron Schwartz

Background: The decrease in glomerular filtration rate (GFR), which is characteristic of obstructive uropathy, was suggested to be associated with attenuated nitric oxide (NO) generation. Since availability of L-arginine, the sole precursor for NO, governs NO synthesis, we aimed to determine the role of glomerular arginine transport in rats subjected to 24 h of bilateral ureteral ligation (BUO). Methods: Glomerular arginine transport was measured by uptake of radiolabeled arginine ([3H]-L-arginine), cationic amino acid transporters (CAT)-1 and -2 and arginases I and II mRNA expression were determined using reverse transcription-polymerase chain reaction. CAT-1, arginase I, and arginase II protein contents were evaluated by Western blotting. Results:L-Arginine transport by freshly harvested glomeruli from BUO rats was significantly augmented than in controls. The aforementioned findings were associated with a significant increase in glomerular CAT-1 mRNA expression, while CAT-2 mRNA was unchanged. Western blotting demonstrated a significant increase in CAT-1 abundance in BUO. Expression of both glomerular arginase I and II mRNA and protein content were significantly elevated in BUO. Conclusions: BUO induces an increase in glomerular arginine transport via upregulation of CAT-1, probably due to increase in arginine utilization by a non-NO pathway.


Nitric Oxide | 2018

Mineralocorticoid receptor blockade improves arginine transport and nitric oxide generation through modulation of cationic amino acid transporter-1 in endothelial cells

Moshe Shashar; Tamar Hod; Tamara Chernichovski; Avital Angel; Shaul Kazan; Ayelet Grupper; Sivan Naveh; Orit Kliuk-Ben Bassat; Talia Weinstein; Idit F. Schwartz

Blockade of the mineralocorticoid receptor (MCR) has been shown to improve endothelial function far beyond blood pressure control. In the current studies we have looked at the effect of MCR antagonists on cationic amino acid transporter-1 (CAT-1), a major modulator of endothelial nitric oxide (NO) generation. Using radio-labeled arginine, {[3H] l-arginine} uptake was determined in human umbilical vein endothelial cells (HUVEC) following incubation with either spironolactone or eplerenone with or without silencing of MCR. Western blotting for CAT-1, PKCα and their phosphorylated forms were performed. NO generation was measured by using Griess reaction assay. Both Spironolactone and eplerenone significantly increased endothelial arginine transport, an effect which was further augmented by co-incubation with aldosterone, and blunted by either silencing of MCR or co-administration of amiloride. Following MCR blockade, we identified two bands for CAT-1. The addition of tunicamycin (an inhibitor of protein glycosylation) or MCR silencing resulted in disappearance of the extra band and prevented the increase in arginine transport. Only spironolactone decreased CAT-1 phosphorylation through inhibition of PKCα (CAT-1 inhibitor). Subsequently, incubation with either MCR antagonists significantly augmented NO2/NO3 levels (stable NO metabolites) and this was attenuated by silencing of MCR or tunicamycin. GO 6076 (PKCα inhibitor) intensified the increase of NO metabolites only in eplerenone treated cells. In conclusion spironolactone and eplerenone augment arginine transport and NO generation through modulation of CAT-1 in endothelial cells. Both MCR antagonists activate CAT-1 by inducing its glycosylation while only spironolactone inhibits PKCα.


Kidney International | 2006

Arginine uptake is attenuated through modulation of cationic amino-acid transporter-1, in uremic rats

Idit F. Schwartz; R. Ayalon; Tamara Chernichovski; Ran Reshef; Gil Chernin; Talia Weinstein; Alex Litvak; Yoram Levo; Doron Schwartz


Atherosclerosis | 2007

Arginine uptake is attenuated, through post-translational regulation of cationic amino acid transporter-1, in hyperlipidemic rats

Idit F. Schwartz; Meirav Ingbir; Tamara Chernichovski; Ran Reshef; Gil Chernin; Alex Litvak; Talia Weinstein; Yoram Levo; Doron Schwartz


Kidney International | 2004

Augmented arginine uptake, through modulation of cationic amino acid transporter-1, increases GFR in diabetic rats.

Idit F. Schwartz; Adrian Iaina; Yishayahu Benedict; Yoram Wollman; Tamara Chernichovski; Eli Brasowski; Faina Misonzhnik; Amir Ben-Dor; Miriam Blum; Yoram Levo; Doron Schwartz

Collaboration


Dive into the Tamara Chernichovski's collaboration.

Top Co-Authors

Avatar

Idit F. Schwartz

Tel Aviv Sourasky Medical Center

View shared research outputs
Top Co-Authors

Avatar

Doron Schwartz

Tel Aviv Sourasky Medical Center

View shared research outputs
Top Co-Authors

Avatar

Talia Weinstein

Tel Aviv Sourasky Medical Center

View shared research outputs
Top Co-Authors

Avatar

Gil Chernin

Tel Aviv Sourasky Medical Center

View shared research outputs
Top Co-Authors

Avatar

Yoram Levo

Tel Aviv Sourasky Medical Center

View shared research outputs
Top Co-Authors

Avatar

Inna Frolkis

Tel Aviv Sourasky Medical Center

View shared research outputs
Top Co-Authors

Avatar

Alex Litvak

Tel Aviv Sourasky Medical Center

View shared research outputs
Top Co-Authors

Avatar

Ayelet Grupper

Tel Aviv Sourasky Medical Center

View shared research outputs
Top Co-Authors

Avatar

Gideon Uretzky

Tel Aviv Sourasky Medical Center

View shared research outputs
Top Co-Authors

Avatar

Itzhak Shapira

Tel Aviv Sourasky Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge